Clinical trials: Hyposalivation
Xerostomia
SaliPen Human Factors Study for OTC Labeling
This Human Factors Validation Testing will assess user interactions to verify the capability of potential users to assess if the study product fits their needs and if they can use it correctly based on the provided Information…
- Trial name
- SaliPen (NCT05058430)
- Testing
- Electrical salivary stimulator system assigned to subjects with xerostomia, No Electrical salivary stimulator system assigned to subjects without xerostomia
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Saliwell Ltd.
Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies
Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases
To evaluate the safety of UTAA09 injection in the treatment of relapsed/refractory (R/R) autoimmune disease (AID). To evaluate the pharmacokinetic (PK) profile of UTAA09 injection in patients with R/R AID.
- Conditions
- Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Systemic Sclerosis, Sjogren's Syndrome
- Trial name
- NCT06417398
- Testing
- T cell injection targeting CD19 chimeric antigen receptor
- Volunteers
- 10 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands
A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia
This study will assess the efficacy and safety of bilateral intra-parotid administration of AAV2-hAQP1 in adults with Grade 2 or Grade 3 radiation-induced late xerostomia.
- Trial name
- AQUAx2 (NCT05926765)
- Testing
- AAV2-hAQP1 Concentration 1, AAV2-hAQP1 Concentration 2, AAV2-hAQP1 Concentration 3
- Where
- 33 sites in United States, Canada and 1 more
- Volunteers
- 290 people
- Sponsor
- MeiraGTx, LLC
Dry Mouth
Bioequivalency Study of 5 mg Piolocarpine Tablets Under Fed Conditions
The objective of this study was the bioequivalence of a Roxane Laboratories' Pilocarpine Tablets, 5 mg, to SALAGEN® Tablets, 5 mg (MGI Pharma) under fed conditions using a single-dose, 2-treatment, 2-period, crossover design.
- Trial name
- NCT00601211
- Testing
- Pilocarpine
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Dry Mouth
Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fed Conditions
The objective of this study was to prove the bioequivalence of Roxane Laboratories' Cevimeline 30 mg under fed conditions
- Trial name
- NCT01903109
- Testing
- Cevimeline
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Sjogren Syndrome, Mixed Connective Tissue Disease
A Study to Evaluate the Safety, Tolerability and Efficacy of MHV370 in Participants With Sjogren's Syndrome (SjS) or Mixed Connective Tissue Disease (MCTD)
This study was a basket trial designed to establish safety, tolerability and efficacy of MHV370 in Sjögren's Syndrome (SjS) and Mixed Connective Tissue Disease (MCTD).
- Trial name
- NCT04988087
- Testing
- MHV370
- Where
- 10 sites in China, Germany and 4 more
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Xerostomia
Effects of Mucoprotective Product on Xerostomia
In the present study with a randomized, cross-over, blind, placebo controlled design, the effects of a salivary substitute product and a new mucoprotective product with similar mechanisms of action but with different composition…
- Trial name
- NCT01316393
- Testing
- XER2020
- Where
- Sweden
- Volunteers
- 20 people
- Sponsor
- Camurus AB
Alopecia Areata, Depressive Episode
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
This study series consists of four related studies and aims to explore and describe many important elements of alopecia areata over three key areas: (1) the current epidemiology of alopecia areata, (2) the prevalence and…
- Conditions
- Alopecia Areata, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorders
- Trial name
- NCT04239521
- Testing
- Exposure of interest (studies 2 & 3).
- Where
- United Kingdom
- Volunteers
- 51,955 people
- Sponsor
- Momentum Data
Sjogren's Syndrome (SS)
An Efficacy and Safety Study of Injectable Ravagalimab to Assess Change in EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) in Adult Participants With Moderately to Severely Active Primary Sjogren's Syndrome (pSS)
Sjogren's syndrome (SS) is a chronic, multisystem autoimmune disease characterized by lacrimal and salivary gland inflammation, with resultant dryness of the eyes and mouth and occasional glandular enlargement.
- Trial name
- NCT05217472
- Testing
- Ravaglimab, Ravagalimab
- Where
- Netherlands
- Sponsor
- AbbVie
Dry Mouth
Bioequivalency Study of 7.5 mg Pilocarpine Under Fed Conditions
The objective of this study was the bioequivalence of a Roxane Laboratories' Pilocarpine tablets, 7.5 mg, to SALAGEN® Tablets, 7.5 mg (MGI) under fed conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence…
- Trial name
- NCT00618059
- Testing
- Pilocarpine
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Sjogren's Syndrome, Sjögren
R-2487 in Patients With Sjogren's Syndrome (SS)
The goal of this study is to determine the safety and tolerability of orally taken probiotic (R-2487) in patients with Sjogren's Syndrome.
- Conditions
- Sjogren's Syndrome, Sjögren, Sjögren Syndrome, Unspecified
- Trial name
- R-2487-SS-01 (NCT06297213)
- Testing
- R-2487
- Volunteers
- 36 people
- Sponsor
- Rise Therapeutics LLC
Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands
Long-term Follow-up of Gene Therapy for Radiation-Induced Xerostomia
This study will assess the long-term safety and efficacy of bilateral intra-parotid administration of AAV2-hAQP1 in adults with Grade 2 or Grade 3 radiation-induced late xerostomia.
- Trial name
- NCT06544798
- Testing
- AAV2-hAQP1
- Where
- 8 sites in United States, Canada
- Volunteers
- 276 people
- Sponsor
- MeiraGTx, LLC
Dry Mouth Associated With Sjogren's Syndrome, Xerostomia
A Safety and Efficacy Study of 552-02 in Subjects With Dry Mouth Associated With Sjogren's Syndrome
This clinical study is to determine whether daily administration of a formulation of 552-02 improves the dry mouth condition in subjects with primary Sjögren's syndrome.
- Trial name
- NCT00852839
- Testing
- 552-02
- Where
- 15 sites in United States
- Volunteers
- 140 people
- Sponsor
- Parion Sciences
Xerostomia in Advanced Cancer Patients
Proof-of-concept (PoC) Study of APD515
A study to look at the effectiveness of a drug called APD515, designed to be applied to the lining inside the mouth, at relieving dryness of the mouth.
- Trial name
- NCT01331746
- Testing
- APD515
- Where
- 11 sites in Denmark, United Kingdom
- Volunteers
- 32 people
- Sponsor
- Acacia Pharma Ltd
Dry Mouth
A Pilot Study to Assess Dry Mouth Relief After Using an Experimental Mouth Rinse
The objective of this pilot study is to determine if an experimental mouth rinse and a marketed dry mouth rinse are more effective in relieving dry mouth compared to water.
- Trial name
- NCT04152642
- Testing
- Marketed Dry Mouth Rinse, Water control, Experimental Dry Mouth Rinse
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Procter and Gamble
Sjogren Syndrome
Biopsy Based Study to Understand Mechanism of Action of Ianalumab in Salivary Glands and Explore Relationships With Clinical Assessments.
This study aims at elucidating the mechanism of action of ianalumab in salivary glands and explore relationships with clinical assessments
- Trial name
- NCT05124925
- Testing
- Ianalumab
- Where
- France
- Volunteers
- 21 people
- Sponsor
- Novartis Pharmaceuticals
Sjogren's Syndrome
Adelphi Primary Sjogren's Syndrome (pSS) Disease Specific Programme (DSP)
Sjogren's Syndrome is a chronic autoimmune disease characterized by sicca (dryness) symptoms of the mouth and eyes. This autoimmune disease is less commonly studied and there are no licensed treatments to treat the underlying…
- Trial name
- NCT03501420
- Testing
- Interview, PSC questionnaire, PRFs
- Where
- United Kingdom
- Volunteers
- 2,223 people
- Sponsor
- GlaxoSmithKline
Systemic Lupus Erythematosus, Systemic Sclerosis
An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease
An exploratory clinical study of the safety and efficacy of YTS109 cell injection in subjects with recurrent/refractory autoimmune disease
- Conditions
- Systemic Lupus Erythematosus, Systemic Sclerosis, Inflammatory Myopathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Trial name
- NCT06379646
- Testing
- YTS109
- Where
- China
- Volunteers
- 6 people
- Sponsor
- China Immunotech (Beijing) Biotechnology Co., Ltd.
Sjogren's Syndrome
Assessment of Inflammatory Biomarkers Expressed in a Sjogren's Population: Effect of a Topical Steroid Intervention
The primary purpose of this study is to quantify the change in expression of biomarkers on the ocular surface of Sjogren's Syndrome participants after treatment with Maxidex.
- Trial name
- NCT00631358
- Testing
- Maxidex, No treatment
- Where
- 2 sites in Canada
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Alcon Research
Primary Sjögren's Syndrome (pSS)
Clinical Study to Investigate the Efficacy of Orally Administered SA001 in Patients With Primary Sjögren's Syndrome
This is a phase2a, multicenter, double-blind, placebo control, randomized study to investigate the efficacy and safety of SA001 in subjects with pSS.
- Trial name
- NCT05269810
- Testing
- SA001 Low dose, SA001 Mid dose, SA001 High dose
- Where
- South Korea
- Volunteers
- 28 people
- Sponsor
- Samjin Pharmaceutical Co., Ltd.